Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on May 19, 2022. The filing addresses specific modifications to a non-transferable subscription rights offering of units that commenced on May 4, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate actions regarding a capital raise rather than operational financial performance.
Material Changes
The Company announced two material changes to its ongoing rights offering:
- Extension of Expiration Date: The offering, originally set to expire on May 23, 2022, has been extended to May 26, 2022, at 5:00 p.m., Eastern Time.
- Revision of Subscription Price: The definition of the "Alternate Price" was amended. The final subscription price per unit will now be the lesser of:
- $3.72; or
- The volume weighted average price (VWAP) of the Company's common stock for the five trading day period through and including May 23, 2022.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. The primary contingency noted is the determination of the final subscription price based on the stock's VWAP through the original expiration date.
Key Facts for Investor Verification
- Verify the final subscription price per unit once the VWAP for the period ending May 23, 2022, is calculated.
- Confirm the total capital raised upon the closing of the offering on the new expiration date of May 26, 2022.
- Review the press release (Exhibit 99.1) for any additional terms or conditions related to the rights offering.